biorasi Blogs

  1. Managing Alzheimer's Trials In A Diverse Global Environment 7/22/2021

    Diagnostics and treatment for Alzheimer’s Disease vary – both around the world and around the block. In this article, read how recognizing the common disparities for these clinical trials, ranging from standards of care to lack of diversity, brings sponsors and other stakeholders closer to maintaining standardized protocols for Alzheimer’s studies.

  2. Pros And Cons: Defining Site Expertise Across Veteran And Research-Naïve Sites 7/2/2021

    Clinical sites that have a great deal of experience are generally sought after, but can often be busy running other trials. It may be beneficial to consider less experienced sites in order to have more trial options. But of course, there are some necessary considerations when turning to these sites.

  3. Blood Disorder Clinical Trials – Adapting To COVID-19 Challenges 7/2/2021

    The spread of COVID-19 has heightened the potential risk of infection for patients suffering from blood disorders. Hematologist Dr. Robert S. Negrin, a new member of Biorasi’s growing Scientific Advisory Board, weighs in on understanding and adapting to changes to blood disorder trials and treatment during the pandemic.

  4. Spotlight On PNH: The Evolution Of Research And Treatment 6/15/2021

    Paroxysmal nocturnal hemoglobinuria (PNH) is defined as an acquired rare disease triggered by a rare mutation in bone marrow stem cells, with patients experiencing production of irregular blood cells. In terms of clinical studies, PNH’s uniqueness presents a number of operational challenges. In this article, Dr. Mehool Patel discusses innovations in the treatment of PNH, the diverse nature of this rare disease, as well as solutions for PNH clinical trial enrollment and availability.

  5. Determining The "ROI" Of Clinical Trial Rescue Before It's Too Late 5/25/2021

    Have you ever put off broaching a difficult conversation about a faltering clinical trial? Early intervention is a sound solution to putting an at-risk trial back on course.

  6. Patient Recruitment Solutions: Optimizing Social Strategies For Clinical Studies 4/21/2021

    Quicker recruitment means more than just a boost of speed. Biorasi has built our reputation as a fast and flexible leader for CRO solutions, and we are constantly striving to find more innovative and efficient methods for enrollment – inclusive of social media strategies.

  7. The Power of Patient Registries - How To Collaborate With Patients To Enhance Orphan Drug Research 6/11/2019

    Patient registries assist orphan drug development by giving manufacturers access to clinical, genetic, and biological data from a large patient population. Using registries, sponsors can better understand the disease, its history, and patients’ needs, all of which benefit clinical trial design and effectiveness.

  8. What To Look for When Selecting A Risk-Based Monitoring Partner 5/22/2019

    There are no concrete instructions when it comes to RBM, and planning a successful RBM design can be challenging. Even so, we believe investing in an experienced partner to help you with RBM design is worthwhile. RBM can be an indispensable tool for your trial’s success. Following is an out of outline a criteria that could be helpful in finding the right RBM specialist.

  9. Is Your Clinical Trial In Need Of A Rescue? 5/8/2019

    Don’t assume your clinical trial will survive endless change orders, extended deadlines, cost overruns, and missed objectives. Recognizing early warning signs that your trial is in trouble, and taking quick decisive action, can often get studies back on track. Improving operations can solve most failure risk factors, thus increasing the odds of success.

  10. Is Gut Microbiome Behind Our Next Breakthrough Therapy? 5/6/2019

    We’re now only beginning to understand how the microbiome influences our health and behavior and vice versa. As we learn more about its connection to a host of diseases and disorders, we expect to see specific bacterial molecules as potential druggable targets.